- +1 551 333 1547
- +44 2070 979277
- live:skype_chat
Point-of-Care Molecular Diagnostics Comprehensive Study by Type (Instruments, Assays & Kits, Software & Services), Application (Sexually Transmitted Infections, Respiratory Diseases, Hepatitis, Gastrointestinal Disorders, Oncology (Breast Cancer, Lung Cancer, Colorectal Cancer, Others), Others), End Users (Clinics, Hospitals, Research Institutes, Diagnostic Centers, Others), Technology (Polymerase Chain Reactions (PCR), Hybridization, DNA Sequencing, Microarray, Other)
Point-of-Care Molecular Diagnostics Market by XX Submarkets | Forecast Years 2024-2030
Point-of-Care Molecular Diagnostics Market Scope
The US Point-of-Care (POC) Molecular Diagnostics market has witnessed significant growth driven by factors such as increasing demand for rapid and accurate diagnostic tests, technological advancements in molecular diagnostics, and the rising prevalence of infectious diseases. POC molecular diagnostics offer several advantages including quick turnaround time, ease of use, and the ability to perform testing at or near the patient's location, which is particularly beneficial in remote or resource-limited settings. Moreover, the COVID-19 pandemic has further accelerated the adoption of POC molecular diagnostics, with tests such as nucleic acid amplification assays playing a crucial role in screening and diagnosing the virus. Key players in the US POC Molecular Diagnostics market include established companies as well as emerging startups, each competing to innovate and expand their product offerings. | Attributes | Details |
|---|---|
| Study Period | 2018-2030 |
| Base Year | 2023 |
| Unit | Value (USD Million) |
| Key Companies Profiled | Siemens Healthcare Private Limited, Agilent Technologies, Inc., BioMérieux, DiaSorin S.p.A., BD, Grifols, Hologic, Inc., Qiagen, Bio-Rad Laboratories, Inc. and Thermo Fisher Scientific Inc. |
| CAGR |
Siemens Healthcare Private Limited, Agilent Technologies, Inc., BioMérieux, DiaSorin S.p.A., BD, Grifols, Hologic, Inc., Qiagen, Bio-Rad Laboratories, Inc. and Thermo Fisher Scientific Inc. are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Sysmex Corporation, F. Hoffmann-la Roche Ltd, DH Life Sciences, LLC., Johnson & Johnson Services, Inc., Abbott, QuidelOrtho Corporation, Co-Diagnostics, Inc., Biocartis and Meridian Bioscience, Inc..
About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.Segmentation Overview
The study have segmented the market of United States Point-of-Care Molecular Diagnostics market by Type , by Application (Sexually Transmitted Infections, Respiratory Diseases, Hepatitis, Gastrointestinal Disorders, Oncology (Breast Cancer, Lung Cancer, Colorectal Cancer, Others) and Others) and Region with country level break-up.On the basis of geography, the market of Point-of-Care Molecular Diagnostics has been segmented into
Report Objectives / Segmentation Covered
By Type
- Instruments
- Assays & Kits
- Software & Services
By Application
- Sexually Transmitted Infections
- Respiratory Diseases
- Hepatitis
- Gastrointestinal Disorders
- Oncology (Breast Cancer, Lung Cancer, Colorectal Cancer, Others)
- Others
By End Users
- Clinics
- Hospitals
- Research Institutes
- Diagnostic Centers
- Others
By Technology
- Polymerase Chain Reactions (PCR)
- Hybridization
- DNA Sequencing
- Microarray
- Other
By Regions
- 1. Market Overview
- 1.1. Introduction
- 1.2. Scope/Objective of the Study
- 1.2.1. Research Objective
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Factor Analysis
- 3.1. Porters Five Forces
- 3.2. Supply/Value Chain
- 3.3. PESTEL analysis
- 3.4. Market Entropy
- 3.5. Patent/Trademark Analysis
- 4. United States Point-of-Care Molecular Diagnostics, by Type, Application, End Users and Technology (value) (2018-2023)
- 4.1. Introduction
- 4.2. United States Point-of-Care Molecular Diagnostics (Value)
- 4.2.1. United States Point-of-Care Molecular Diagnostics by: Type (Value)
- 4.2.1.1. Instruments
- 4.2.1.2. Assays & Kits
- 4.2.1.3. Software & Services
- 4.2.2. United States Point-of-Care Molecular Diagnostics by: Application (Value)
- 4.2.2.1. Sexually Transmitted Infections
- 4.2.2.2. Respiratory Diseases
- 4.2.2.3. Hepatitis
- 4.2.2.4. Gastrointestinal Disorders
- 4.2.2.5. Oncology (Breast Cancer, Lung Cancer, Colorectal Cancer, Others)
- 4.2.2.6. Others
- 4.2.3. United States Point-of-Care Molecular Diagnostics by: End Users (Value)
- 4.2.3.1. Clinics
- 4.2.3.2. Hospitals
- 4.2.3.3. Research Institutes
- 4.2.3.4. Diagnostic Centers
- 4.2.3.5. Others
- 4.2.4. United States Point-of-Care Molecular Diagnostics by: Technology (Value)
- 4.2.4.1. Polymerase Chain Reactions (PCR)
- 4.2.4.2. Hybridization
- 4.2.4.3. DNA Sequencing
- 4.2.4.4. Microarray
- 4.2.4.5. Other
- 4.2.1. United States Point-of-Care Molecular Diagnostics by: Type (Value)
- 5. Point-of-Care Molecular Diagnostics: Manufacturers/Players Analysis
- 5.1. Competitive Landscape
- 5.1.1. Market Share Analysis
- 5.1.1.1. Top 3
- 5.1.1.2. Top 5
- 5.1.1. Market Share Analysis
- 5.2. Peer Group Analysis (2023)
- 5.3. BCG Matrix
- 5.4. Company Profile
- 5.4.1. Siemens Healthcare Private Limited
- 5.4.1.1. Business Overview
- 5.4.1.2. Products/Services Offerings
- 5.4.1.3. Financial Analysis
- 5.4.1.4. SWOT Analysis
- 5.4.2. Agilent Technologies, Inc.
- 5.4.2.1. Business Overview
- 5.4.2.2. Products/Services Offerings
- 5.4.2.3. Financial Analysis
- 5.4.2.4. SWOT Analysis
- 5.4.3. BioMérieux
- 5.4.3.1. Business Overview
- 5.4.3.2. Products/Services Offerings
- 5.4.3.3. Financial Analysis
- 5.4.3.4. SWOT Analysis
- 5.4.4. DiaSorin S.p.A.
- 5.4.4.1. Business Overview
- 5.4.4.2. Products/Services Offerings
- 5.4.4.3. Financial Analysis
- 5.4.4.4. SWOT Analysis
- 5.4.5. BD
- 5.4.5.1. Business Overview
- 5.4.5.2. Products/Services Offerings
- 5.4.5.3. Financial Analysis
- 5.4.5.4. SWOT Analysis
- 5.4.6. Grifols
- 5.4.6.1. Business Overview
- 5.4.6.2. Products/Services Offerings
- 5.4.6.3. Financial Analysis
- 5.4.6.4. SWOT Analysis
- 5.4.7. Hologic, Inc.
- 5.4.7.1. Business Overview
- 5.4.7.2. Products/Services Offerings
- 5.4.7.3. Financial Analysis
- 5.4.7.4. SWOT Analysis
- 5.4.8. Qiagen
- 5.4.8.1. Business Overview
- 5.4.8.2. Products/Services Offerings
- 5.4.8.3. Financial Analysis
- 5.4.8.4. SWOT Analysis
- 5.4.9. Bio-Rad Laboratories, Inc.
- 5.4.9.1. Business Overview
- 5.4.9.2. Products/Services Offerings
- 5.4.9.3. Financial Analysis
- 5.4.9.4. SWOT Analysis
- 5.4.10. Thermo Fisher Scientific Inc.
- 5.4.10.1. Business Overview
- 5.4.10.2. Products/Services Offerings
- 5.4.10.3. Financial Analysis
- 5.4.10.4. SWOT Analysis
- 5.4.1. Siemens Healthcare Private Limited
- 5.1. Competitive Landscape
- 6. United States Point-of-Care Molecular Diagnostics Sale, by Type, Application, End Users and Technology (value) (2025-2030)
- 6.1. Introduction
- 6.2. United States Point-of-Care Molecular Diagnostics (Value)
- 6.2.1. United States Point-of-Care Molecular Diagnostics by: Type (Value)
- 6.2.1.1. Instruments
- 6.2.1.2. Assays & Kits
- 6.2.1.3. Software & Services
- 6.2.2. United States Point-of-Care Molecular Diagnostics by: Application (Value)
- 6.2.2.1. Sexually Transmitted Infections
- 6.2.2.2. Respiratory Diseases
- 6.2.2.3. Hepatitis
- 6.2.2.4. Gastrointestinal Disorders
- 6.2.2.5. Oncology (Breast Cancer, Lung Cancer, Colorectal Cancer, Others)
- 6.2.2.6. Others
- 6.2.3. United States Point-of-Care Molecular Diagnostics by: End Users (Value)
- 6.2.3.1. Clinics
- 6.2.3.2. Hospitals
- 6.2.3.3. Research Institutes
- 6.2.3.4. Diagnostic Centers
- 6.2.3.5. Others
- 6.2.4. United States Point-of-Care Molecular Diagnostics by: Technology (Value)
- 6.2.4.1. Polymerase Chain Reactions (PCR)
- 6.2.4.2. Hybridization
- 6.2.4.3. DNA Sequencing
- 6.2.4.4. Microarray
- 6.2.4.5. Other
- 6.2.1. United States Point-of-Care Molecular Diagnostics by: Type (Value)
- 7. Appendix
- 7.1. Acronyms
- 8. Methodology and Data Source
- 8.1. Methodology/Research Approach
- 8.1.1. Research Programs/Design
- 8.1.2. Market Size Estimation
- 8.1.3. Market Breakdown and Data Triangulation
- 8.2. Data Source
- 8.2.1. Secondary Sources
- 8.2.2. Primary Sources
- 8.3. Disclaimer
- 8.1. Methodology/Research Approach
List of Tables
- Table 1. Point-of-Care Molecular Diagnostics: by Type(USD Million)
- Table 2. Point-of-Care Molecular Diagnostics: by Application(USD Million)
- Table 3. Point-of-Care Molecular Diagnostics: by End Users(USD Million)
- Table 4. Point-of-Care Molecular Diagnostics: by Technology(USD Million)
- Table 5. Company Basic Information, Sales Area and Its Competitors
- Table 6. Company Basic Information, Sales Area and Its Competitors
- Table 7. Company Basic Information, Sales Area and Its Competitors
- Table 8. Company Basic Information, Sales Area and Its Competitors
- Table 9. Company Basic Information, Sales Area and Its Competitors
- Table 10. Company Basic Information, Sales Area and Its Competitors
- Table 11. Company Basic Information, Sales Area and Its Competitors
- Table 12. Company Basic Information, Sales Area and Its Competitors
- Table 13. Company Basic Information, Sales Area and Its Competitors
- Table 14. Company Basic Information, Sales Area and Its Competitors
- Table 15. Point-of-Care Molecular Diagnostics: by Type(USD Million)
- Table 16. Point-of-Care Molecular Diagnostics: by Application(USD Million)
- Table 17. Point-of-Care Molecular Diagnostics: by End Users(USD Million)
- Table 18. Point-of-Care Molecular Diagnostics: by Technology(USD Million)
- Table 19. Research Programs/Design for This Report
- Table 20. Key Data Information from Secondary Sources
- Table 21. Key Data Information from Primary Sources
List of Figures
- Figure 1. Porters Five Forces
- Figure 2. Supply/Value Chain
- Figure 3. PESTEL analysis
- Figure 4. United States Point-of-Care Molecular Diagnostics: by Type USD Million (2018-2023)
- Figure 5. United States Point-of-Care Molecular Diagnostics: by Application USD Million (2018-2023)
- Figure 6. United States Point-of-Care Molecular Diagnostics: by End Users USD Million (2018-2023)
- Figure 7. United States Point-of-Care Molecular Diagnostics: by Technology USD Million (2018-2023)
- Figure 8. United States Point-of-Care Molecular Diagnostics share by Players 2023 (%)
- Figure 9. United States Point-of-Care Molecular Diagnostics share by Players (Top 3) 2023(%)
- Figure 10. United States Point-of-Care Molecular Diagnostics share by Players (Top 5) 2023(%)
- Figure 11. BCG Matrix for key Companies
- Figure 12. Siemens Healthcare Private Limited Revenue, Net Income and Gross profit
- Figure 13. Siemens Healthcare Private Limited Revenue: by Geography 2023
- Figure 14. Agilent Technologies, Inc. Revenue, Net Income and Gross profit
- Figure 15. Agilent Technologies, Inc. Revenue: by Geography 2023
- Figure 16. BioMérieux Revenue, Net Income and Gross profit
- Figure 17. BioMérieux Revenue: by Geography 2023
- Figure 18. DiaSorin S.p.A. Revenue, Net Income and Gross profit
- Figure 19. DiaSorin S.p.A. Revenue: by Geography 2023
- Figure 20. BD Revenue, Net Income and Gross profit
- Figure 21. BD Revenue: by Geography 2023
- Figure 22. Grifols Revenue, Net Income and Gross profit
- Figure 23. Grifols Revenue: by Geography 2023
- Figure 24. Hologic, Inc. Revenue, Net Income and Gross profit
- Figure 25. Hologic, Inc. Revenue: by Geography 2023
- Figure 26. Qiagen Revenue, Net Income and Gross profit
- Figure 27. Qiagen Revenue: by Geography 2023
- Figure 28. Bio-Rad Laboratories, Inc. Revenue, Net Income and Gross profit
- Figure 29. Bio-Rad Laboratories, Inc. Revenue: by Geography 2023
- Figure 30. Thermo Fisher Scientific Inc. Revenue, Net Income and Gross profit
- Figure 31. Thermo Fisher Scientific Inc. Revenue: by Geography 2023
- Figure 32. United States Point-of-Care Molecular Diagnostics: by Type USD Million (2025-2030)
- Figure 33. United States Point-of-Care Molecular Diagnostics: by Application USD Million (2025-2030)
- Figure 34. United States Point-of-Care Molecular Diagnostics: by End Users USD Million (2025-2030)
- Figure 35. United States Point-of-Care Molecular Diagnostics: by Technology USD Million (2025-2030)
List of companies from research coverage that are profiled in the study
- Siemens Healthcare Private Limited
- Agilent Technologies, Inc.
- BioMérieux
- DiaSorin S.p.A.
- BD
- Grifols
- Hologic, Inc.
- Qiagen
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific Inc.
Additional players considered in the study are as follows:
Sysmex Corporation
,
F. Hoffmann-la Roche Ltd
,
DH Life Sciences, LLC.
,
Johnson & Johnson Services, Inc.
,
Abbott
,
QuidelOrtho Corporation
,
Co-Diagnostics, Inc.
,
Biocartis
,
Meridian Bioscience, Inc.
Select User Access Type
Key Highlights of Report
May 2024
229 Pages
65 Tables
Base Year: 2023
Coverage: 15+ Companies; 18 Countries
Request Sample Pages
Budget constraints? Get in touch with us for special pricing
Check Discount Now
Talk to Our Experts
Want to Customize Study?
"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."
Frequently Asked Questions (FAQ):
The key segments that are playing vital role in Point-of-Care Molecular Diagnostics Market are by type [Instruments, Assays & Kits and Software & Services], by end use application [Sexually Transmitted Infections, Respiratory Diseases, Hepatitis, Gastrointestinal Disorders, Oncology (Breast Cancer, Lung Cancer, Colorectal Cancer, Others) and Others].
The Point-of-Care Molecular Diagnostics Market is gaining popularity and expected to see strong valuation by 2030.